Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD
5 affiliations
- 1Department of Nephrology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
- 2Department of Cardiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
- 3Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, Kansas, USA
- 4Kidney Disease: Improving Global Outcomes, Brussels, Belgium
- 5Centre for Kidney and Bladder Health, University College London, UK
Abstract
Introduction: Mineralocorticoid receptor antagonists (MRAs) have reemerged as a key strategy for cardiorenal risk reduction after the success of finerenone in large trials. However, high costs have limited the global accessibility, raising a relevant question: whether widely available steroidal MRAs provide comparable efficacy and safety. In the absence of direct comparative trials, we performed a network meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses-2020 guidelines (CRD420251152929). Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus for randomized controlled trials (RCTs) evaluating MRAs in chronic kidney disease (CKD). A Bayesian network meta-analysis compared MRAs with standard care. The primary outcome was change in urine albumin-to-creatinine ratio (UACR). Secondary outcomes included change in estimated glomerular filtration rate (eGFR), hyperkalemia, and adverse events. Meta-regression explored effect modification by baseline eGFR and follow-up duration. Results: A total of 32 trials ( N = 21,678) were analyzed. All evaluated MRA dose nodes, which significantly reduced UACR, with overlapping antiproteinuric effects. Spironolactone 25 mg and finerenone 20 mg were associated with similar reductions in albuminuria. Mild reductions in eGFR were observed across treatments, consistent with early hemodynamic adaptation largely informed by short-term studies. Hyperkalemia risk relatively increased, without consistent differences between subclasses. Meta-regression showed no association between UACR reduction and follow-up duration or baseline eGFR. Hyperkalemia and other adverse events were more frequent with longer follow-up and lower baseline eGFR. Conclusion: Both steroidal and nonsteroidal MRAs were associated with reductions in albuminuria, with substantial overlap in antiproteinuric effects. Our findings underscore the continuing clinical relevance of steroidal MRAs as accessible therapeutic options and support further head-to-head outcome-driven trials in CKD.
Related
- Effects of mineralocorticoid receptor antagonists on coronary microcirculation: a mini-review.
- Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease: an updated systematic review and meta-analysis of randomized controlled trials
- Renin, Major Adverse Cardiovascular Outcomes, and the Use of Mineralocorticoid Receptor Antagonists in Hypertension
- Peripherally acting μ-opioid receptor antagonists for recovery of bowel function after radical cystectomy: a systematic review and meta-analysis
- Neurokinin-3 receptor antagonists for vasomotor symptoms in menopause and breast cancer survivorship.
BibTeX
@article{korucu2026dosespecific,
title = {{Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD}},
author = {Berfu Korucu and Ayse Colak and Reem Mustafa and Amy Earley and David C. Wheeler},
journal = {Kidney International Reports},
year = {2026},
month = sep,
doi = {10.1016/j.ekir.2026.107084},
url = {https://doi.org/10.1016/j.ekir.2026.107084},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD
AU - Berfu Korucu
AU - Ayse Colak
AU - Reem Mustafa
AU - Amy Earley
AU - David C. Wheeler
PY - 2026
DA - 2026/09/17
JO - Kidney International Reports
DO - 10.1016/j.ekir.2026.107084
UR - https://doi.org/10.1016/j.ekir.2026.107084
AB - Introduction: Mineralocorticoid receptor antagonists (MRAs) have reemerged as a key strategy for cardiorenal risk reduction after the success of finerenone in large trials. However, high costs have limited the global accessibility, raising a relevant question: whether widely available steroidal MRAs provide comparable efficacy and safety. In the absence of direct comparative trials, we performed a network meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses-2020 guidelines (CRD420251152929). Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus for randomized controlled trials (RCTs) evaluating MRAs in chronic kidney disease (CKD). A Bayesian network meta-analysis compared MRAs with standard care. The primary outcome was change in urine albumin-to-creatinine ratio (UACR). Secondary outcomes included change in estimated glomerular filtration rate (eGFR), hyperkalemia, and adverse events. Meta-regression explored effect modification by baseline eGFR and follow-up duration. Results: A total of 32 trials ( N = 21,678) were analyzed. All evaluated MRA dose nodes, which significantly reduced UACR, with overlapping antiproteinuric effects. Spironolactone 25 mg and finerenone 20 mg were associated with similar reductions in albuminuria. Mild reductions in eGFR were observed across treatments, consistent with early hemodynamic adaptation largely informed by short-term studies. Hyperkalemia risk relatively increased, without consistent differences between subclasses. Meta-regression showed no association between UACR reduction and follow-up duration or baseline eGFR. Hyperkalemia and other adverse events were more frequent with longer follow-up and lower baseline eGFR. Conclusion: Both steroidal and nonsteroidal MRAs were associated with reductions in albuminuria, with substantial overlap in antiproteinuric effects. Our findings underscore the continuing clinical relevance of steroidal MRAs as accessible therapeutic options and support further head-to-head outcome-driven trials in CKD.
SN - 2468-0249
ER -